Page 21 - Astrazeneca

CEO says AstraZeneca may to run new global trial of Covid vaccine: Report

AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage amid questions over the results from its late-stage study

Top headlines: Modi to visit Serum Institute, farmers' protests, more

Union Agriculture Minister Narendra Singh Tomar said the government is ready to talk with farmers on December 3, and resolve differences

Britain asks regulator to assess AstraZeneca-Oxford vaccine amid questions

The British government said it has formally asked the country's medicines regulator to assess whether a coronavirus vaccine developed by AstraZeneca and Oxford University should be authorised for use

Russia's Sputnik V developers call on AstraZeneca to try combining vaccines

Russia said its Sputnik V vaccine is 92% effective at protecting people from COVID-19, according to interim trial results

CEO says AstraZeneca likely to run new global Covid vaccine trial: Report

"Now that we've found what looks like a better efficacy we have to validate this, so we need to do an additional study," Soriot was quoted as saying

AstraZeneca-Oxford vaccine safe, Indian trials progressing smoothly: SII

Serum Institute of India said the Covid-19 vaccine developed by AstraZeneca and Oxford University is safe and effective, and the Indian trials are progressing smoothly

AstraZeneca aims to impact 10 mn diabetics by 2023, starts awareness drive

India will have 115 mn diabetics by 2030. Forty-four per cent of patients hospitalised for heart failure have type-2 diabetes

Thailand to sign Covid-19 vaccine agreement with Oxford-AstraZeneca

The announcement comes as other countries in the region like the Philippines prepare to sign similar deals with AstraZeneca

Top headlines: Questions over Oxford vaccine data, Vedanta under pressure

Modi bats for One Nation One Election, Keki Mistry says NPAs in real estate will inch up , and more top headlines of the day

AstraZeneca faces more Covid-19 vaccine questions after manufacturing error

Oxford said a difference in manufacturing processes led to later phases of the trials having a half-dose given instead of a full one

AstraZeneca Covid-19 vaccine's 90% efficacy came in younger trial group

The vaccine being developed with Oxford University was 90 per cent effective when a half-dose was given before a full-dose booster, the partners said on Monday

India Coronavirus Dispatch: How do you vaccinate a billion people?

AstraZeneca's manufacturing error, lack of transparency in Indian vaccine trials, should Indian states consider lockdowns again?-news relevant to India's fight against Covid-19

AstraZeneca manufacturing error clouds coronavirus vaccine study results

AstraZeneca and Oxford University have acknowledged a manufacturing error that is raising questions about preliminary results of their experimental Covid-19 vaccine

Explainer: When and how will Covid-19 vaccines become available?

If regulators approve any of the vaccines in coming weeks, the distribution could begin almost immediately

India Coronavirus Dispatch: AstraZeneca vaccine is key even at 70% efficacy

Why vaccines should be a public good, Keeping indoor air clean can reduce spread of SARS-CoV-2, and is favipiravir good for Covid-19?-news relevant to India's fight against the pandemic

AstraZeneca must prove it won't profit from Covid-19 vaccine: Non-govt body

The price of its candidate has been set at about $3 per dose, against at least four times more for other candidates

MARKETS: Indices end at record closing peaks; Nifty settles above 13,000

All that happened in the markets today

Affordable Covid-19 vaccines will test world's intellectual property regime

An intellectual property regime that is not flexible enough to manage the coronavirus crisis is one that will break under the weight of that techno-dystopia.

Sensex, Nifty march higher on Covid-19 vaccine progress news; ONGC rises 6%

After touching a record intra-day high of 44,271.15, Sensex ended 194.90 points or 0.44 per cent higher at 44,077.15

Euro zone business activity shrinks but Covid vaccine hopes boost optimism

The bloc's economy is on track for its first double-dip recession in nearly a decade as a second wave of the coronavirus sweeps across Europe, a Reuters poll suggested last week